Aripiprazole - In acute mania associated with bipolar I disorder
Aripiprazole - In acute mania associated with bipolar I disorder
复制标题
DOI：
10.2165/00023210-200418060-00007
复制
发表时间：
2004-01-01
期刊：
影响因子：
6
通讯作者：
Perry, CM
中科院分区：
文献类型：
--
作者：
Lyseng-Williamson, KA;Perry, CM
阿立哌唑是一种口服喹啉酮（喹诺酮），是一种新型非典型抗精神病药，对多巴胺 D-2 和血清素 5-HT1A 受体具有部分激动剂活性，对 5-HT2A 受体具有拮抗剂活性。阿立哌唑起效迅速（早在第 4 天），可有效治疗患有急性躁狂或混合发作的 I 型双相情感障碍患者。在为期 3 周的安慰剂对照试验中，阿立哌唑在改善躁狂症状（根据年轻躁狂评定量表总分的平均变化来定义）方面通常比安慰剂更有效，并且在一项为期 12 周的比较试验中表现出优于氟哌啶醇的有效性（在继续治疗的患者中，反应率为 50% vs 28.4%）。对于既往经历过躁狂发作的 I 型双相情感障碍稳定患者，症状复发的时间明显更长。在一项为期 26 周的复发预防研究中，阿立哌唑优于安慰剂。阿立哌唑通常具有良好的耐受性，并且与体重增加、血清催乳素升高或临床显着的 QTc 间期延长无关。阿立哌唑的锥体外系症状量表评分与基线相比的变化很小（
Aripiprazole, an oral quinolinone (carbostyril), is a novel atypical antipsychotic that has partial agonist activity at dopamine D-2 and serotonin 5-HT1A receptors, and antagonist activity at 5-HT2A receptors.Aripiprazole had a rapid onset of action (as early as day 4) and was effective in the treatment of patients with bipolar I disorder experiencing an acute manic or mixed episode. Aripiprazole was generally significantly more effective than placebo in improving manic symptoms (as defined by a mean change in Young Mania Rating Scale Total Score) in 3-week placebo-controlled trials, and demonstrated superior effectiveness to haloperidol (response rate 50% vs 28.4% in patients remaining on treatment) in a 12-week comparative trial.The time to relapse of symptoms in stabilised patients with bipolar I disorder who previously experienced a manic episode was significantly longer with aripiprazole than with placebo in a 26-week relapse prevention study.Aripiprazole was generally well tolerated and was not associated with weight gain, serum prolactin elevation or clinically significant QTc interval prolongation.Changes from baseline in extrapyramidal symptom scale scores with aripiprazole were small (